Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
JAGX 
Jaguar Animal Health Inc (JAGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: JAGX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $25.5
1 Year Target Price $25.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -86.03% | Avg. Invested days 14 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.86M USD | Price to earnings Ratio 0.06 | 1Y Target Price 25.5 |
Price to earnings Ratio 0.06 | 1Y Target Price 25.5 | ||
Volume (30-day avg) 2 | Beta 0.61 | 52 Weeks Range 1.57 - 33.25 | Updated Date 10/17/2025 |
52 Weeks Range 1.57 - 33.25 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 37.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -268.78% |
Management Effectiveness
Return on Assets (TTM) -37.42% | Return on Equity (TTM) -319.25% |
Valuation
Trailing PE 0.06 | Forward PE - | Enterprise Value 35614398 | Price to Sales(TTM) 0.67 |
Enterprise Value 35614398 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 3.02 | Enterprise Value to EBITDA -0.63 | Shares Outstanding 3707121 | Shares Floating 1736937 |
Shares Outstanding 3707121 | Shares Floating 1736937 | ||
Percent Insiders 20.01 | Percent Institutions 0.39 |
Upturn AI SWOT
Jaguar Animal Health Inc
Company Overview
History and Background
Jaguar Animal Health Inc. was founded to develop and commercialize gastrointestinal products for companion and production animals. The company has faced challenges in achieving profitability and has undergone restructuring.
Core Business Areas
- Napo Pharmaceuticals: Focuses on human health products. Jaguar Animal Health Inc. previously owned Napo Pharmaceuticals.
- Animal Health Products: Develops and commercializes prescription and non-prescription products for gastrointestinal health in animals. KROYA and Canalevia are examples.
Leadership and Structure
Information on the current leadership team and organizational structure is not readily available publicly due to the company's delisting and restructuring. Historically, the structure involved a CEO, CFO, and heads of research and development, marketing, and sales.
Top Products and Market Share
Key Offerings
- Canalevia: A drug for the treatment of chemotherapy-induced diarrhea in dogs. Market share data is unavailable due to limited sales. Competitors include anti-diarrheal medications and supportive therapies.
- KROYA: A gastrointestinal support product for horses. Market share data is unavailable due to limited sales. Competitors include other gastrointestinal supplements and medications.
Market Dynamics
Industry Overview
The animal health industry is competitive and growing, driven by increasing pet ownership and demand for advanced veterinary care and animal production. The pharmaceutical sector is dominated by large players.
Positioning
Jaguar Animal Health Inc. aimed to carve a niche in the gastrointestinal health market for animals. However, it faced difficulties in gaining market traction and competing with larger, established companies.
Total Addressable Market (TAM)
The animal health market is estimated to be worth billions of dollars. Jaguar Animal Health Inc. has struggled to capture a meaningful share of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary drug platform
- Unique product formulations (historically)
- Targeted solutions for gastrointestinal issues
Weaknesses
- Limited financial resources
- Small sales and marketing infrastructure
- History of net losses
- Delisting from stock exchange (formerly NASDAQ)
- Restricted access to capital
Opportunities
- Partnerships with larger animal health companies
- Expansion into new geographic markets (historically considered)
- Development of new product applications
- Capitalize on rising pet ownership
Threats
- Competition from established animal health companies
- Regulatory hurdles
- Patent expirations
- Economic downturn affecting pet spending
- Availability of alternative treatments
Competitors and Market Share
Key Competitors
- ELAN
- ZOETIS
- MRK
Competitive Landscape
Jaguar Animal Health Inc. faced significant disadvantages compared to its larger competitors in terms of resources, market reach, and brand recognition. Smaller percentage share due to going dark.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was limited due to challenges in sales, marketing, and competition. The company has experienced more contraction than growth.
Future Projections: Future projections are uncertain given the company's current financial condition and delisting.
Recent Initiatives: Recent initiatives are not publicly known, as Jaguar Animal Health Inc. has limited public presence.
Summary
Jaguar Animal Health Inc. faced significant challenges in commercializing its products and achieving profitability. The company's small size and limited resources hindered its ability to compete effectively with larger players. The delisting from the stock exchange further exacerbates financial constraints. Any potential for future success relies on strategic partnerships or a significant turnaround in its financial position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (Historical)
- Industry Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The data may be outdated due to the company's limited reporting. Past performance is not indicative of future results. Market share data are estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jaguar Animal Health Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2015-05-13 | Founder, CEO, President & Director Ms. Lisa A. Conte | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://jaguar.health |
Full time employees 49 | Website https://jaguar.health | ||
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.